Author:
Ramezani Amitis,Sorouri Rahim,Haji Maghsoudi Saiedeh,Dahmardeh Sarah,Doroud Delaram,Sadat Larijani Mona,Eybpoosh Sana,Mostafavi Ehsan,Olyaeemanesh Alireza,Salehi-Vaziri Mostafa,Bavand Anahita,Zarghani Ghazaleh,Moradi Ladan,Ashrafian Fatemeh,Bagheri Amiri Fahimeh,Mashayekhi Parisa,Tahmasebi Zahra,Biglari Alireza
Abstract
AbstractThe optimal booster vaccine schedule against COVID-19 is still being explored. The present study aimed at assessment of the immunogenicity and antibody persistency of inactivated-virus based vaccine, BBIP-CorV and protein-subunit based vaccines, PastoCovac/Plus through heterologous and homologous prime-boost vaccination. Totally, 214 individuals who were previously primed with BBIBP-CorV vaccines were divided into three arms on their choice as heterologous regimens BBIBP-CorV/PastoCovac (n = 68), BBIBP-CorV/PastoCovac Plus (n = 72) and homologous BBIBP-CorV (n = 74). PastoCovac booster recipients achieved the highest rate of anti-Spike IgG titer rise with a fourfold rise in 50% of the group. Anti-RBD IgG and neutralizing antibody mean rise and fold rise were almost similar between the PastoCovac and PastoCovac Plus booster receivers. The antibody durability results indicated that the generated antibodies were persistent until day 180 in all three groups. Nevertheless, a higher rate of antibody titer was seen in the heterologous regimen compared to BBIP-CorV group. Furthermore, no serious adverse event was recorded. The protein subunit-based booster led to a stronger humoral immune response in comparison with the BBIP-CorV booster receivers. Both the protein subunit boosters neutralized SARS-CoV-2 significantly more than BBIP-CorV. Notably, PastoCovac protein subunit-based vaccine could be successfully applied as a booster with convenient immunogenicity and safety profile.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Abu-Raddad, L. J. et al. SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks. medRxiv 11, 05005 (2021).
2. Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185(3), 467–84.e15 (2022).
3. Salehi-Vaziri, M. et al. SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up. Microbial Pathogenes. 161, 105296 (2021).
4. Sofian, M. et al. SARS-CoV-2 viral shedding and associated factors among COVID-19 inpatients and outpatients. Interdiscip. Perspect. Infect. Dis. 2022, 1411106 (2022).
5. Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing covid-19 vaccines at pandemic speed. N. Engl. J. Med. https://doi.org/10.1056/NEJMp2005630 (2020).
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献